about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsClonal origin and spread of metastatic prostate cancerThe structure and function of NKAIN2-a candidate tumor suppressorMutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide TherapyOxidative Stress Resistance in Metastatic Prostate Cancer: Renewal by Self-EatingProstate Cancer: Epigenetic Alterations, Risk Factors, and TherapyERG induces taxane resistance in castration-resistant prostate cancerEvolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerMolecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular networkEvaluation of ERG responsive proteome in prostate cancerRecurrent prostate cancer genomic alterations predict response to brachytherapy treatmentShared common variants in prostate cancer and blood lipids.Predominance of ERG-negative high-grade prostate cancers in African American men.Disease pathways at the Rat Genome Database Pathway Portal: genes in context-a network approach to understanding the molecular mechanisms of disease.Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancerGene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.Extracting the Benefit of Nexrutine® for Cancer Prevention.Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG statusActive Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice.Circulating microRNA signature for the diagnosis of very high-risk prostate cancerRegulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cellsBiomarkers for prostate cancer: present challenges and future opportunities.Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo.Evolution of androgen receptor targeted therapy for advanced prostate cancer.Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.Nucleic acid-based tissue biomarkers of urologic malignancies.Biomarkers in prostate cancer: new era and prospective.Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Functional significance of aberrantly expressed microRNAs in prostate cancer.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.Molecular biomarkers to guide precision medicine in localized prostate cancer.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.A Network Biology Approach Identifies Molecular Cross-Talk between Normal Prostate Epithelial and Prostate Carcinoma Cells.Amplification of the 9p13.3 chromosomal region in prostate cancer.
P2860
Q26738703-87F8656F-38F6-4746-A04C-F46701BB8463Q26752510-395A74D5-FBD4-47DC-A78B-82E64F30C1CAQ26752873-4A7F2BE8-700B-4719-A178-A09054DBE645Q26771844-5BC8EF08-44E5-4FCF-99D7-9B2CB9AD6551Q27334558-53CF712B-5681-43CA-9F52-77AF73394EDBQ27334935-4D143EDB-56B4-467C-A237-2CE07FEB6DB0Q28073470-0EBFD0B9-D2F6-4E60-8867-9273900F9ABEQ30602046-36D1033E-9D55-4293-BC0A-8FD632704F39Q30938412-4C194CCE-1E44-48ED-83FA-5BF028295992Q33677773-5AB77809-474C-4A5C-89A4-B953C4DF885CQ33822319-16907A4A-7F50-4762-BE93-742656ED22DCQ33852664-D6F25705-C598-44EB-B474-9BBE4C680F4BQ34001263-DBCB3278-FD22-4D88-BEA3-CF53E242F106Q34265721-306AF730-A7CF-4AF6-A658-26E07EC18B79Q34312452-BF616CB9-ED8E-4151-B0CA-D8B0565630ACQ35163551-9F680D68-0CBC-4966-B919-06B5D24D09F9Q35223291-F3264F3D-AD30-44DF-94C0-9BB9C843FFF3Q35407284-158C75AF-1385-4425-BEFF-82B88EA24CF7Q36053741-237372BC-D64C-4C86-A599-109A9353F261Q36236997-57A8CB5E-7556-45FE-BAD2-99215FEC7E79Q36381818-343AB16A-A316-4EF9-A1E9-B117A5AF71B3Q37029385-4DD80030-6A3C-4CA1-9579-9067AF853DBEQ37030008-9A161F2C-0006-476F-AD68-34255436B35AQ37281617-CFCA901B-8F51-4B4D-B9F4-0283A7CD08AFQ37301786-E66B0231-119E-422F-A014-5CFE2C78ED04Q37474443-F5802EDA-521D-40D4-B9EA-8DA698D9DA94Q37501345-5C45293E-C50F-4BF8-8D9C-4F8004138C2FQ37708945-4B6BA1A3-7A59-4D9B-BE9D-5559696DF559Q38212716-3EAFFFCE-4898-470D-AEE6-99A56C73D72AQ38216129-EC794284-96C8-4F9E-84B8-B68F08F2FAD5Q38216131-ADB349ED-E3C2-49E4-9659-7D6DB484F845Q38232466-7B1DB461-9D57-4267-B3F1-AFDA75278E04Q38309205-6838B521-5144-4711-83EF-DF53C4323939Q38323461-D5A2D8E0-270F-4275-8C56-8CD4A5485E8BQ38644658-35D4E08C-6679-4F87-86FA-CB1D44F848D1Q38657057-0FCC5AA5-C3E5-45A6-94F8-2CBE8FE62CF3Q38668635-D519BDB9-7551-4820-9D76-8DAB8031B8C6Q38774228-7B9F3401-3130-4B05-9028-F9A00E12CF6AQ38774786-26FAD980-AF8A-4920-816B-FE42EC2E7984Q38778571-A534E2F7-CB14-43A1-8B7A-E37C2E9D545E
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The mutational landscape of prostate cancer
@ast
The mutational landscape of prostate cancer
@en
The mutational landscape of prostate cancer
@nl
type
label
The mutational landscape of prostate cancer
@ast
The mutational landscape of prostate cancer
@en
The mutational landscape of prostate cancer
@nl
prefLabel
The mutational landscape of prostate cancer
@ast
The mutational landscape of prostate cancer
@en
The mutational landscape of prostate cancer
@nl
P2093
P2860
P50
P3181
P1433
P1476
The mutational landscape of prostate cancer
@en
P2093
Anders Bjartell
Chris H Bangma
Henrik Grönberg
Zoran Culig
P2860
P304
P3181
P356
10.1016/J.EURURO.2013.05.029
P407
P577
2013-05-18T00:00:00Z